Denali Therapeutics, Inc. engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth in 2013 and is headquartered in San Francisco, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548
Debt
Debt-to-Equity RatioN/A
Current Ratio12.18
Quick Ratio12.17
Price-To-Earnings
Trailing P/E Ratio-2.67
Forward P/E Ratio-21.27
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book2.98
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees130
Outstanding Shares94,810,000
Market Cap$1.43 billion
Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions
What is Denali Therapeutics' stock symbol?
Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."
How were Denali Therapeutics' earnings last quarter?
Denali Therapeutics Inc (NASDAQ:DNLI) issued its earnings results on Thursday, August, 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.39. The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $3 million. View Denali Therapeutics' Earnings History.
When is Denali Therapeutics' next earnings date?
What price target have analysts set for DNLI?
4 brokers have issued 1 year price targets for Denali Therapeutics' shares. Their forecasts range from $23.00 to $25.00. On average, they anticipate Denali Therapeutics' stock price to reach $24.00 in the next year. This suggests a possible upside of 52.5% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.
What is the consensus analysts' recommendation for Denali Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.
Who are some of Denali Therapeutics' key competitors?
Some companies that are related to Denali Therapeutics include Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).
Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the folowing people:
- Ryan J. Watts, President, Chief Executive Officer & Director
- Alexander Schuth, Chief Operating Officer & Secretary
- Steve E. Krognes, CFO, Treasurer & Principal Accounting Officer
- Carole Ho, Chief Medical Officer & Head-Development
- Cindy Dunkle, Head-Human Resources
When did Denali Therapeutics IPO?
(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.
Has Denali Therapeutics been receiving favorable news coverage?
Press coverage about DNLI stock has been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Denali Therapeutics earned a coverage optimism score of 0.20 on Accern's scale. They also gave media coverage about the company an impact score of 48.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Denali Therapeutics.
Who are Denali Therapeutics' major shareholders?
Denali Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (8.51%), Baillie Gifford & Co. (5.66%), BlackRock Inc. (1.19%), Jasper Ridge Partners L.P. (0.30%), Millennium Management LLC (0.18%) and Schwab Charles Investment Management Inc. (0.08%). View Institutional Ownership Trends for Denali Therapeutics.
Which major investors are selling Denali Therapeutics stock?
Which major investors are buying Denali Therapeutics stock?
DNLI stock was purchased by a variety of institutional investors in the last quarter, including Jasper Ridge Partners L.P., Millennium Management LLC, Baillie Gifford & Co., BlackRock Inc., Citadel Advisors LLC, Swiss National Bank, Raymond James Financial Services Advisors Inc. and Dynamic Technology Lab Private Ltd. View Insider Buying and Selling for Denali Therapeutics.
How do I buy shares of Denali Therapeutics?
Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Denali Therapeutics' stock price today?
One share of DNLI stock can currently be purchased for approximately $15.74.
How big of a company is Denali Therapeutics?
Denali Therapeutics has a market capitalization of $1.43 billion. The company earns $-88,180,000.00 in net income (profit) each year or ($5.89) on an earnings per share basis. Denali Therapeutics employs 130 workers across the globe.
How can I contact Denali Therapeutics?
Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.
MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
